2023-05-23 05:36:16 ET
- Clarivate ( NYSE: CLVT ) extended its material transfer agreement (MTA) with the FDA for an another three years, giving the agency continued access to Clarivate's OFF-X solution which provides integrated preclinical toxicity, clinical and post-marketing adverse event data, visualizations and analytics.
- Clarivate said that as the collaboration enters its sixth year, the FDA will continue to use OFF-X to identify potential adverse events linked with molecular targets and new and marketed medicines and its utility in the regulatory review process.
- "The agreement between the FDA and Clarivate will enable increased preparedness as researchers and drug safety professionals look to anticipate and monitor potential safety liabilities across all phases of drug R&D and post market," said Gavin Coney, vice president, Partnerships at Clarivate.
-
More on Clarivate
- Clarivate: A Great Recovery Play
- Clarivate: Organic Growth To Drive EBITDA Expansion
For further details see:
Clarivate, FDA extend pact for safety intelligence solution OFF-X